ClinicalTrials.gg
CompletedNCT07691268Updated Jul 8, 2026

Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions

A Phase 1 interventional study of Administration of UI111 and Administration of UIC202006 in Dyslipidemia, sponsored by Korea United Pharm. Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Korea United Pharm. Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Feb 2025, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.

Enrollment
100th of 124
44 · median 80
Started
2025
with 13 others
Phase 1
58 of 155
7 open now
Registered
153rd of 155
by date

Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 100th largest by enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2025, is one of 58 in phase 1, and was the 153rd registered.

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Dyslipidemias with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Phase 1 study to evaluate the safety and the pharmacokinetics of "UI111" and "UIC202006" in healthy adult volunteers under fed state conditions

- Open-label, randomized, single-dose, 2-sequence, 4-period, crossover design

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are at least 19 years of age at the time of the screening visit.
  • Subjects who weigh at least 50 kg (at least 45 kg for females) and have a (BMI) between 18.0 and 30.0 kg/m², inclusive, at the time of the screening visit. ☞ BMI (kg/m²) = body weight (kg) / [height (m)]²
  • Subjects who have no congenital or chronic diseases and no pathological symptoms or findings based on the medical examination at the time of the screening visit.
  • Subjects who are determined to be eligible for participation in the study by the Principal Investigator (or a delegated sub-investigator) based on the results of diagnostic assessments, including hematology, blood chemistry, serology, urinalysis, (ECG), and any other evaluations performed according to the characteristics of the product.
  • Subjects who agree that they and/or their spouse or partner will use medically acceptable methods (excluding hormonal contraceptives) from the first administration of the investigational product until 7 days after the last administration of the investigational product to prevent pregnancy, and who agree not to donate sperm or ova during this period.*

    • Medically acceptable contraceptive methods include an intrauterine device (IUD), vasectomy, tubal ligation, or the combined use of barrier methods (e.g., male condom, female condom, cervical cap, diaphragm, or contraceptive sponge). If spermicide is used, it must be combined with at least two barrier methods.
  • Subjects who have received and understood a full explanation of the purpose and procedures of the study, the characteristics of the investigational product, and the anticipated adverse events, and who voluntarily provide written prior to participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have a current or past history of diseases involving the gastrointestinal, cardiovascular, endocrine, respiratory, hematologic/oncologic, infectious, renal and genitourinary, psychiatric, neurological, musculoskeletal, immune, otorhinolaryngological (ear, nose, and throat), dermatologic, or ophthalmologic systems.
  • Subjects with a history of gastrointestinal surgery that may affect drug absorption (except for uncomplicated appendectomy or hernia repair), or with current gastrointestinal diseases that may affect drug absorption.
  • Subjects who have taken medications known to induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month prior to the first administration of the product, or any medication that may interfere with the conduct of this study within 10 days prior to the first administration of the investigational product. However, participation may be permitted after consideration of the pharmacokinetic and pharmacodynamic characteristics of the medication, including its potential interaction with the investigational product and elimination half-life.
  • Subjects who have participated in another clinical trial or bioequivalence study and received an investigational product within 6 months prior to the first administration of the investigational product in this study.
  • Subjects who have donated whole blood within 8 weeks, donated blood components (e.g., or plasma donation) within 2 weeks, or received a blood transfusion within 4 weeks prior to the first administration of the investigational product.
  • Subjects who, within 1 month prior to the first administration of the investigational product, meet any of the following criteria:

For males: average alcohol consumption exceeding 21 standard drinks per week. For females: average alcohol consumption exceeding 14 standard drinks per week. (One standard drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer.) Smoking more than an average of 20 cigarettes per day. - Subjects who meet any of the following criteria: Known to the investigational product or any of its components. Hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

- Subjects with any of the following conditions: Severe hepatic impairment (e.g., biliary cirrhosis, active liver disease, or persistent unexplained elevations of transaminases exceeding 3 × the [ULN]).

Moderate to severe renal impairment (estimated [eGFR] \< 60 mL/min/1.73 m²).

A history of photoallergic or phototoxic reactions during treatment with fibrates or ketoprofen.

Gallbladder disease. Acute or chronic pancreatitis associated with hypertriglyceridemia. Myopathy; a history of rhabdomyolysis or myopathy associated with statins or fibrates; or a history of creatine phosphokinase (CPK) elevations ≥5 × ULN during previous statin therapy.

Interstitial lung disease. A history of pulmonary embolism. Severe myasthenia gravis or ocular myasthenia.

  • Subjects whom the Principal Investigator (or a delegated sub-investigator) considers unsuitable for participation in this study for any reason other than the inclusion and exclusion criteria listed above.
  • Female subjects who are pregnant, suspected to be pregnant, or breastfeeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    UI111

    Test

    Drug: Administration of UI111

  • Active comparator
    UIC202006

    Reference

    Drug: Administration of UIC202006

Interventions

  • DrugAdministration of UI111

    1cap, once a day

  • DrugAdministration of UIC202006

    1cap, once a day

06

What researchers measure

Primary outcomes

  1. AUCt

    Time frame: 0 to 12hours(Active ingredient A), 0 to 72hours(Active ingredient B)

  2. Cmax

    Time frame: 0 to 12hours(Active ingredient A), 0 to 72hours(Active ingredient B)

07

Study locations

1 site
  • H plus Yangji Hospital
    Seoul, Gwanak-gu 08779, South Korea
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Mar 2025, 0 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 0 months is below that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 8, 2026
StartActual
Feb 13, 2025
Primary completionActual
Mar 10, 2025
CompletionActual
Mar 26, 2025
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07691268
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Feb 13, 2025
Primary completion
Mar 10, 2025
Completion
Mar 26, 2025
Last update
Jul 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion